WEBINAR | Transforming Oncology Drug Development: Insights from Healthcare Providers on the Frontlines of Cancer Care
It is an exciting time for oncology drug development, characterized by rapid innovation and significant advancements in personalized medicine, and the landscape is witnessing a surge in clinical trials exploring novel mechanisms of action, biomarkers, and combination therapies to overcome resistance and enhance efficacy.
What treatment modalities are healthcare providers (HCPs) most excited about? What groundbreaking research is piquing their interest? Are antibody drug conjugates (ADCs) and theranostics—potentially transformative therapies getting the spotlight of late—living up to their hype?
These questions and more will be answered through a survey of HCPs attending the European Society for Medical Oncology (ESMO) annual meeting—one of the premier events in the oncology community, bringing together thousands of oncologists, researchers, and healthcare professionals from around the world to share the latest scientific developments, research findings, and clinical advancements in cancer treatment.
Join us for an engaging webinar that will unveil insights from oncologists surveyed at the ESMO 2024 conference. Our experts will identify and explore the data that oncologists consider most impactful from the conference and provide a closer look at the transformative potential of antibody drug conjugates (ADCs) and theranostics. We’ll also examine the oncology drug development landscape, highlighting the surge in innovative trials and the strategic shifts in treatment approaches.
In this webinar, attendees will:
- Understand how new data unveiled at ESMO 2024 may impact the future of cancer treatment
- Review the status of current antibody drug conjugates in oncology and how to get the next generation of ADCs into first-in human trials
- Get the latest information on the constantly evolving field of theranostics and its promise to significantly improve treatment outcomes
Speakers
Wouter Bartholomeus, MD
Executive Medical Director Oncology & Hematology, Syneos Health
Patrick Kelly, MD
Vice President, Medical Management, Oncology & Hematology, Syneos Health
Prateet Minhas, PhD
Managing Director, Consulting, Syneos Health
Related Content
Want to learn more? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:
How Prepared Is Your Oncology Team for Their FDA Advisory Committee Meeting?
Readiness Assessment: What Strategies Can You Deploy to Improve Diversity in Your Oncology Trials?
